全文获取类型
收费全文 | 573篇 |
免费 | 50篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 50篇 |
妇产科学 | 7篇 |
基础医学 | 96篇 |
口腔科学 | 4篇 |
临床医学 | 39篇 |
内科学 | 116篇 |
皮肤病学 | 9篇 |
神经病学 | 39篇 |
特种医学 | 35篇 |
外科学 | 84篇 |
综合类 | 14篇 |
预防医学 | 22篇 |
眼科学 | 9篇 |
药学 | 42篇 |
中国医学 | 3篇 |
肿瘤学 | 52篇 |
出版年
2023年 | 6篇 |
2022年 | 9篇 |
2021年 | 21篇 |
2020年 | 7篇 |
2019年 | 13篇 |
2018年 | 25篇 |
2017年 | 15篇 |
2016年 | 16篇 |
2015年 | 23篇 |
2014年 | 19篇 |
2013年 | 23篇 |
2012年 | 27篇 |
2011年 | 26篇 |
2010年 | 15篇 |
2009年 | 19篇 |
2008年 | 25篇 |
2007年 | 20篇 |
2006年 | 27篇 |
2005年 | 17篇 |
2004年 | 19篇 |
2003年 | 13篇 |
2002年 | 24篇 |
2001年 | 14篇 |
2000年 | 14篇 |
1999年 | 8篇 |
1998年 | 7篇 |
1997年 | 4篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1992年 | 14篇 |
1991年 | 12篇 |
1990年 | 5篇 |
1989年 | 5篇 |
1988年 | 8篇 |
1987年 | 11篇 |
1986年 | 6篇 |
1985年 | 4篇 |
1984年 | 10篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 12篇 |
1980年 | 7篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1973年 | 8篇 |
1970年 | 3篇 |
1969年 | 4篇 |
1968年 | 3篇 |
1967年 | 3篇 |
1966年 | 4篇 |
排序方式: 共有625条查询结果,搜索用时 0 毫秒
621.
Hariri A Lopresti DC Miller FJ Kuo MD 《Journal of vascular and interventional radiology : JVIR》2007,18(2):313-316
The KPS Rinspirator (Kerberos Proximal Solutions, Cupertino, Calif.) is a new thrombectomy device that operates by manually controlled, simultaneous, intravessel infusion and aspiration of fluid to cause localized clot dissolution. We evaluate the ability of the KPS Rinspirator to treat acute (<3 days) and subacute (3-7 days) deep venous and arteriovenous graft thrombosis in 4 patients and 13 vessels (2 arteriovenous grafts and 11 deep veins). Technical and clinical success was achieved in the two patients with acute arteriovenous graft thromboses. Therefore, in our experience, successful "rinspiration" was achieved in acute thrombosis of arteriovenous grafts. 相似文献
622.
A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines 总被引:5,自引:0,他引:5
Heineman TC Schleiss M Bernstein DI Spaete RR Yan L Duke G Prichard M Wang Z Yan Q Sharp MA Klein N Arvin AM Kemble G 《The Journal of infectious diseases》2006,193(10):1350-1360
BACKGROUND: Human cytomegalovirus (HCMV) infection acquired in utero often results in severe consequences, including mental retardation and deafness. Although not evaluated for this indication, live attenuated HCMV vaccines based on the Towne strain are well-tolerated and have demonstrated moderate efficacy in other clinical settings. METHODS: To produce live HCMV vaccine candidates that retain the excellent safety profile of the Towne strain but are more immunogenic, the genomes of the Towne strain and the unattenuated HCMV Toledo strain were recombined to yield 4 independent chimeric vaccine candidates. These vaccine candidates were evaluated in 20 HCMV-seropositive persons, in a phase 1, double-blinded, placebo-controlled trial. Participants received a single dose of vaccine or placebo, and the safety and tolerability of the vaccine candidates were evaluated. RESULTS: There was no difference in systemic symptoms between the vaccine and placebo recipients. As a group, vaccine recipients experienced more injection-site reactions than did placebo recipients; however, these were generally minor and short-lived. Vaccine virus could not be detected in blood, urine, or saliva samples obtained from any vaccine recipient. CONCLUSIONS: The Towne/Toledo chimeric vaccine candidates were well tolerated and did not cause systemic infection. Additional human trials are warranted to further evaluate the potential of these vaccine candidates as live virus vaccines. 相似文献
623.
Koeberl DD Sun BD Damodaran TV Brown T Millington DS Benjamin DK Bird A Schneider A Hillman S Jackson M Beaty RM Chen YT 《Gene therapy》2006,13(17):1281-1289
The deficiency of glucose-6-phosphatase (G6Pase) underlies life-threatening hypoglycemia and growth retardation in glycogen storage disease type Ia (GSD-Ia). An adeno-associated virus (AAV) vector encoding G6Pase was pseudotyped as AAV8 and administered to 2-week-old GSD-Ia mice (n = 9). Median survival was prolonged to 7 months following vector administration, in contrast to untreated GSD-Ia mice that survived for only 2 weeks. Although GSD-Ia mice were initially growth-retarded, treated mice increased fourfold in weight to normal size. Blood glucose was partially corrected by 2 weeks following treatment, whereas blood cholesterol normalized. Glucose-6-phosphatase activity was partially corrected to 25% of the normal level at 7 months of age in treated mice, and blood glucose during fasting remained lower in treated, affected mice than in normal mice. Glycogen storage was partially corrected in the liver by 2 weeks following treatment, but reaccumulated to pre-treatment levels by 7 months old (m.o.). Vector genome DNA decreased between 3 days and 3 weeks in the liver following vector administration, mainly through the loss of single-stranded genomes; however, double-stranded vector genomes were more stable. Although CD8+ lymphocytic infiltrates were present in the liver, partial biochemical correction was sustained at 7 m.o. The development of efficacious AAV vector-mediated gene therapy could significantly reduce the impact of long-term complications in GSD-Ia, including hypoglycemia, hyperlipidemia and growth failure. 相似文献
624.
625.
R Whitley A Arvin C Prober L Corey S Burchett S Plotkin S Starr R Jacobs D Powell A Nahmias 《The New England journal of medicine》1991,324(7):450-454
BACKGROUND. In a controlled trial comparing acyclovir with vidarabine in the treatment of neonatal herpes simplex virus (HSV) infection, we found no significant difference between the treatments in adjusted mortality and morbidity. Hence, we sought to define for the entire cohort (n = 202) the clinical characteristics that best predicted the eventual outcome in these neonates. METHODS. Data were gathered prospectively at 27 centers between 1981 and 1988 in infants less than one month of age who had virologically confirmed HSV infection. We examined the outcomes by multivariate analyses of 24 variables. Disease was classified in one of three categories based on the extent of the involvement at entry into the trial: infection confined to skin, eyes, or mouth; encephalitis; or disseminated infection. RESULTS AND CONCLUSIONS. There were no deaths among the 85 infants with localized HSV infection. The mortality rate was significantly higher in the 46 neonates with disseminated infection (57 percent) than in the 71 with encephalitis (15 percent). In addition, the risk of death was increased in neonates who were in or near coma at entry (relative risk, 5.2), had disseminated intravascular coagulopathy (relative risk, 3.8), or were premature (relative risk, 3.7). In babies with disseminated disease, HSV pneumonitis was also associated with greater mortality (relative risk, 3.6). In the survivors, morbidity was most frequent in infants with encephalitis (relative risk, 4.4), disseminated infection (relative risk, 2.1), seizures (relative risk, 3.0), or infection with HSV type 2 (relative risk, 4.9). With HSV infection limited to the skin, eyes, or mouth, the presence of three or more recurrences of vesicles was associated with an increased risk of neurologic impairment as compared with two or fewer recurrences. 相似文献